Apellis Pharmaceuticals (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 3,371 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 3,371 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $73,386.67. Following the transaction, the insider directly owned 78,353 shares of the company’s stock, valued at $1,705,744.81. This trade represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mark Jeffrey Delong also recently made the following trade(s):

• On Tuesday, January 20th, Mark Jeffrey Delong sold 1,334 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $19.79, for a total value of $26,399.86.
• On Tuesday, January 13th, Mark Jeffrey Delong sold 1,780 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $22.19, for a total value of $39,498.20.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $21.76 on Friday. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10. The firm has a market capitalization of $2.75 billion, a PE ratio of 70.18 and a beta of 0.31. Apellis Pharmaceuticals, Inc. has a 1-year low of $16.10 and a 1-year high of $30.91. The business’s fifty day moving average price is $23.02 and its two-hundred day moving average price is $23.52.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share. The company’s revenue for the quarter was up 133.0% compared to the same quarter last year. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Apellis Pharmaceuticals by 207.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock worth $667,000 after acquiring an additional 19,944 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Apellis Pharmaceuticals by 26.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock valued at $6,730,000 after purchasing an additional 64,742 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Apellis Pharmaceuticals by 4.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock worth $4,869,000 after purchasing an additional 9,747 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of Apellis Pharmaceuticals by 118.4% in the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock worth $479,000 after purchasing an additional 11,862 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Apellis Pharmaceuticals by 1,146.2% in the 1st quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock worth $522,000 after purchasing an additional 22,052 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on APLS shares. HC Wainwright decreased their price objective on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Robert W. Baird increased their price target on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. TD Cowen lowered their price target on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Wells Fargo & Company reduced their price objective on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Wall Street Zen upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Twelve investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.53.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re?rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near?term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.